Uncommon Immune-Mediated Disease 8) Perianal Fistula (ํ•ญ๋ฌธ์ฃผ์œ„๋ˆ„๊ณต)

1. Etiology

  • PAF = anal furunculosis
  • ํ•ญ๋ฌธ ์ฃผ๋ณ€์— 1๊ฐœ ์ด์ƒ์˜ ๊ตฌ๋ฉ + ๊ทธ ์ฃผ์œ„๋กœ ๊ถค์–‘
  • ์ฒ˜์Œ์—๋Š” ๋ฌผ๋ฆฌ๊ฑฐ๋‚˜, ํ•ญ๋ฌธ๋‚ญ์ด ํ„ฐ์ง€๊ฑฐ๋‚˜ ํ•œ ์ค„ ์•Œ์•˜๋Š”๋ฐ โ†’ ์•„์ง ๋ช…ํ™•ํ•˜์ง€๋Š” ์•Š์ง€๋งŒ, ๋ฉด์—ญ๋งค๊ฐœ๋กœ ์ผ์–ด๋‚˜๋Š” ๋งŒ์„ฑ ์—ผ์ฆ์„ฑ ์งˆํ™˜์ž„์„ ์•Œ๊ฒŒ ๋จ.
  • ๋ฆผํ”„๊ตฌ, plasma cell, eosinophil, macrophage ๋“ฑ์ด ์นจ์œค๋˜์–ด ์žˆ์—ˆ์Œ.
  • IL-2, TNF-ฮฑ ๋“ฑ์ด ๊ณ ๋†๋„๋กœ ํฌํ•จ๋œ ์„ธํฌ๋“ค์ด ์ฃผ๋ฅผ ์ด๋ฃธ.
    • IL-2 โ‡’ cyclosporine์„ ๋งŽ์ด ์”€.
  • ๋Œ€ํ˜•๊ฒฌ์—์„œ ์ฃผ๋กœ ๋ฐœ์ƒ โ†’ ์šฐ๋ฆฌ๋‚˜๋ผ์—์„œ๋Š” ๋งŽ์ด ๋ณด์ด์ง€ ์•Š์Œ.
    • German Sheperds (>80%) : ์ด ํ’ˆ์ข…์—์„œ ๋งค์šฐ ํŠน์ง•์ 
    • Irish Setter, Labrador Retriever, Old English Sheepdog

2. Clinical Features and Diagnosis

  • Excessive grooming, hematochezia(ํ˜ˆ๋ณ€), tenesmus(์ด๊ธ‰ํ›„์ฆ), dyschezia(๋…ธ๋ ฅ์„ฑ ๋ฐฐ๋ณ€), fecal incontinence, rectal stricture(ํ˜‘์ฐฉ)
  • Severe pain โ†’ ๋น„ํŠน์ด์  ์ „์‹  ์ฆ์ƒ (lethargy, inappetence, weight loss)
  • ํ•„๊ธฐ
    • ๊ตฌ๋ฉ์ด ์ƒ๊ธฐ๋‹ˆ๊นŒ ๊ฐœ๊ฐ€ ์ž๊พธ ํ•ฅ๊ฒŒ ๋จ.
    • ์ดˆ๊ธฐ์—๋Š” ์  ๊ฐ™์€ ์ž‘์€ ๊ตฌ๋ฉ โ†’ ์ปค์ง€๋ฉด ํ„ฐ์ ธ์„œ ํฐ ๊ตฌ๋ฉ์ด ๋จ.
    • ๊ณ„์† ํ•ฅ์œผ๋ฉด์„œ ์—ผ์ฆ ์‹ฌํ™”, ๊ฐ์—ผ, ๋† ์‹ฌํ™”
    • ๊ตฌ๋ฉ์„ ํ†ตํ•ด ์—ผ์ฆ ๋ฌผ์งˆ์ด ์ฐจ๊ฑฐ๋‚˜ ๋†์ด ์ƒ๊ธธ ์ˆ˜ ์žˆ์Œ.
    • ๊ตฌ๋ฉ์ด ๋งŽ์ด ์ปค์ ธ์„œ ์ง์žฅ๊ณผ ์—ฐ๊ฒฐ๋˜๋ฉด, ๋˜ฅ์ด ํ˜๋Ÿฌ๋‚˜์˜ค๊ฑฐ๋‚˜.. ์‹ฌํ•ด์งˆ ์ˆ˜ ์žˆ์Œ.
    • ์ƒ๊ฐ๋ณด๋‹ค ์•„ํ”„๋‹ค!
    • ํ’ˆ์ข… ์†Œ์ธ, ๋ณ‘๋ ฅ, ์‹ ์ฒด ๊ฒ€์‚ฌ ๋“ฑ์œผ๋กœ ์ง๊ด€์ ์œผ๋กœ ์ง„๋‹จ ๊ฐ€๋Šฅ.
    • ์ง์žฅ ๊ฒ€์‚ฌ๋ฅผ ํ†ตํ•ด์„œ ๋‹ค๋ฅธ ์›์ธ์— ์˜ํ•œ ๊ฒƒ์€ ์•„๋‹Œ์ง€ ๊ผญ ๊ฐ๋ณ„.
    • ํ•ญ๋ฌธ์— ๋Œ€ํ•œ ๊ฒ€์‚ฌ๋ฅผ ๊ผญ ํ•ด์ฃผ์‹œ๊ณ , ๊ฝค ์•„ํ”ˆ ์งˆํ™˜์ด๋‹ˆ ๊ผญ ์ง„์ •์„ ํ•ด์ฃผ์‹œ๊ณ ,,
    • ๊ตฌ๋ฉ์„ ํ†ตํ•ด ์นดํ…Œํ„ฐ(๋์ด ๋ง๋ž‘)๋ฅผ ๋„ฃ์–ด ์„ธ์ฒ™ + ๊นŠ์ด ์ธก์ • + ๊ฐœํ†ต์„ฑ์ด ์žˆ๋Š”์ง€ ๋“ฑ์„ ํ™•์ธ.
    • ๊นจ๋—ํ•œ ํ™˜๊ฒฝ์—์„œ ํ•˜๋Š” ๊ฑธ ์ถ”์ฒœ.
    • ๊ฐ์—ผ์ด ์žˆ์œผ๋ฉด ํ•ญ์ƒ์ œ ๋“ฑ์˜ ์ฒ˜๋ฐฉ๋„ ํ•„์š”.
์ดˆ๊ธฐ์ดˆ๊ธฐ ๊ตฌ๋ฉ + ํ„ฐ์ง„ ๊ตฌ๋ฉ๊ฝค ์ง„ํ–‰๋œ ์ƒํƒœ
  • ๋ณ€์„ ์ž˜ ๋ชป ๋ณผ ์ˆ˜ ์žˆ์Œ.
    • ์•ˆ์ชฝ ๊ธธ์ด ์ข์•„์ ธ ์žˆ๊ฑฐ๋‚˜, ์—ผ์ฆ์ด ์‹ฌํ•ด์„œ ๋ถ™์–ด๋ฒ„๋ฆฌ๊ฑฐ๋‚˜, ์•„ํŒŒ์„œ ํž˜์„ ๋ชป ์ฃผ๊ฑฐ๋‚˜..

3. Treatment & Prognosis

  • Cyclosporine
    • 60-100%๋Š” ์น˜๋ฃŒ๋จ
    • ๋ถˆํ–‰ํžˆ๋„ 30-60% ์ •๋„๋Š” ์•ฝ์„ ๋จน์œผ๋ฉด์„œ๋„ ์žฌ๋ฐœํ•  ์ˆ˜ ์žˆ๊ณ ,, ๊ทธ๋ž˜์„œ ํ‰์ƒ ์•ฝ์„ ๋จน์–ด์•ผ ํ•  ์ˆ˜๋„ ์žˆ์Œ.
    • ๋น„์‹ธ์„œ ์ง€๊ฐ‘ ๋ˆˆ๋ฌผ..ใ… ใ… 
  • PDS, azathioprine
    • ๊ฒฝ์ œ์  ์ด์œ ๋กœ ์„ ํƒํ•˜๊ธฐ๋„ ํ•จ
    • ํ™•์‹คํžˆ ์น˜๋ฃŒ ์„ฑ๊ณต๋ฅ ์€ ๋–จ์–ด์ง
  • Tacrolimus
    • Topical, ๊ตญ์†Œ ์ œ์ œ, ์—ฐ๊ณ  ์ œ์ œ
    • ๊ต‰์žฅํžˆ ๊ฐ•๋ ฅํ•œ ๋ฉด์—ญ ์–ต์ œ์ œ, ์‚ฌ๋žŒ๋„ ์žฅ๊ฐ‘ ๊ปด์•ผ ํ•˜๊ณ , ๊ฐœ๋„ ๋„ฅ์นผ๋ผ๋ฅผ ์”Œ์›Œ ํ•ฅ์ง€ ๋ชปํ•˜๊ฒŒ ํ•ด์•ผ ํ•จ.
    • ์—ฐ๊ณ ์ง€๋งŒ ๊ฝค ๋น„์‹ผ ํŽธ
    • ์•„์ฃผ ์‹ฌํ•˜์ง€ ์•Š์„ ๋•Œ ๊ตญ์†Œ์ ์œผ๋กœ ์ ์šฉํ•˜๊ฑฐ๋‚˜, ๋„ˆ๋ฌด ์‹ฌํ•ด์„œ ์ฒ˜์Œ์— ์—ผ์ฆ์„ ์ข€ ์ผ€์–ดํ•ด์•ผ ํ•  ๋•Œ
  • Supportive care
    • ํ™˜๊ฒฝ ๊นจ๋—ํ•˜๊ฒŒ, ๋ฐฐ๋ณ€ ์™„ํ™”์ œ(lactulose ๋“ฑ), ๋„ˆ๋ฌด ์•„ํŒŒํ•˜๋ฉด ์ง„ํ†ต์ œ
  • ์˜ˆํ›„ : ์™„์น˜๊ฐ€ ์ž˜ ์•ˆ ๋˜๊ณ  ์žฌ๋ฐœ์ด ์ž˜ ๋จ
    • ์™ธ๊ตญ์—์„œ๋Š” ์•ˆ๋ฝ์‚ฌ๋„ ๊ณ ๋ ค๋จ; ์•ฝ์ด ๋„ˆ๋ฌด ๋น„์Œˆ, ๋ณ€์„ ์งˆ์งˆ ํ˜๋ฆฌ๋‹ค ๋ณด๋‹ˆ ์‚ถ์˜ ์งˆ์ด ์ €ํ•˜๋˜๊ณ  ๋ณดํ˜ธ์ž์—๊ฒŒ ๋ถ€๋‹ด์ด ํผ..